Sinphar Pharmaceutical Co Ltd (1734) — Cash Flow Reinvestment Rate
Sinphar Pharmaceutical Co Ltd (1734) has a Cash Flow Reinvestment Rate of 0.87x as of March 2026, reinvesting NT$101.07 Million (capex NT$101.07 Million ) from operating cash flow of NT$116.42 Million. Check 1734 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Sinphar Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2003–2025)
Historical reinvestment intensity for Sinphar Pharmaceutical Co Ltd across 22 annual periods. Explore 1734 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Sinphar Pharmaceutical Co Ltd (2003–2025)
Year-by-year capital reinvestment analysis for Sinphar Pharmaceutical Co Ltd. For live market cap and broader valuation context, see market cap of Sinphar Pharmaceutical Co Ltd.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.39x | NT$230.30 Million | NT$584.66 Million | NT$200.94 Million | ▼ -40.6% |
| 2024 | 0.66x | NT$393.33 Million | NT$593.51 Million | NT$256.71 Million | ▼ -69.1% |
| 2023 | 2.14x | NT$635.50 Million | NT$296.37 Million | NT$300.94 Million | ▲ +387.1% |
| 2022 | 0.44x | NT$187.21 Million | NT$425.30 Million | NT$153.44 Million | ▼ -63.1% |
| 2021 | 1.19x | NT$161.77 Million | NT$135.54 Million | NT$161.44 Million | ▲ +7.3% |
| 2020 | 1.11x | NT$162.79 Million | NT$146.39 Million | NT$157.77 Million | ▼ -73.5% |
| 2018 | 4.19x | NT$333.38 Million | NT$79.50 Million | NT$255.69 Million | ▲ +318.9% |
| 2017 | 1.00x | NT$220.09 Million | NT$219.87 Million | NT$171.00 Million | ▼ -63.3% |
| 2016 | 2.73x | NT$238.05 Million | NT$87.18 Million | NT$224.85 Million | ▲ +67.1% |
| 2015 | 1.63x | NT$458.26 Million | NT$280.53 Million | NT$412.04 Million | ▼ -27.5% |
| 2014 | 2.25x | NT$335.00 Million | NT$148.58 Million | NT$294.29 Million | ▼ -9.7% |
| 2013 | 2.50x | NT$741.65 Million | NT$297.09 Million | NT$598.16 Million | ▲ +9.4% |
| 2012 | 2.28x | NT$375.19 Million | NT$164.45 Million | NT$375.19 Million | ▲ +42.3% |
| 2011 | 1.60x | NT$361.69 Million | NT$225.58 Million | NT$361.69 Million | ▲ +43.2% |
| 2010 | 1.12x | NT$292.75 Million | NT$261.49 Million | NT$292.75 Million | ▲ +57.9% |
| 2009 | 0.71x | NT$219.71 Million | NT$309.94 Million | NT$219.71 Million | ▼ -17.6% |
| 2008 | 0.86x | NT$233.25 Million | NT$271.01 Million | NT$233.25 Million | ▼ -63.7% |
| 2007 | 2.37x | NT$414.90 Million | NT$174.85 Million | NT$414.90 Million | ▲ +58.5% |
| 2006 | 1.50x | NT$249.44 Million | NT$166.57 Million | NT$249.44 Million | ▼ -3.1% |
| 2005 | 1.55x | NT$188.76 Million | NT$122.09 Million | NT$188.76 Million | ▲ +68.1% |
| 2004 | 0.92x | NT$160.79 Million | NT$174.81 Million | NT$160.79 Million | ▼ -57.3% |
| 2003 | 2.16x | NT$260.50 Million | NT$120.84 Million | NT$260.50 Million | — |